Written and maintained by CASRAI Editorial Board
Published
On this page
Form FDA 2253, “Transmittal of Advertisements and Promotional Labeling for Drugs and Biologics for Human Use”, is the cover form that accompanies every submission of promotional materials for an FDA-regulated human drug or biologic. Each form covers one application number, lists each promotional piece on its own line, and goes to the FDA review office with a copy of the current professional labeling. Since 24 June 2021 the submission itself must be electronic for human prescription drugs, according to the FDA CDER page read on 2026-11-12.
What FDA Form 2253 is and who files it
The form is a transmittal: it tells FDA which application the promotional material belongs to, which pieces are enclosed, when each piece was or will be first disseminated, and who at the applicant answers questions. It does not itself contain the advertisement. For prescription drugs, the Office of Prescription Drug Promotion (OPDP) in CDER receives the submissions; for biologics regulated by CBER, the submission goes to CBER’s document control center, as described in the FDA instructions supplement dated 11/21 (the version read on 2026-11-12; the document states that previous editions are obsolete).
Applicants file it. In the regulations, 21 CFR 314.81(b)(3)(i) (read on Cornell LII, 2026-11-12) requires the applicant for a prescription drug product to submit specimens of mailing pieces and any other labeling or advertising devised for promotion of the drug product at the time of initial dissemination of the labeling and at the time of initial publication of the advertisement. Each such submission is to be accompanied by a completed transmittal Form FDA-2253 and a copy of the current professional labeling. A sample of the drug may be omitted from mailing pieces designed to contain samples.
What goes on the form, box by box
The data table below lists items 1 to 13 as described in the FDA instructions. Some points deserve emphasis because they are where submissions tend to differ from what an applicant expects.
Application type and number (item 2)
The instructions list NDA, ANDA, BLA and PMA as application types, and CDER IND only for promotional materials for an authorized CDER emergency use authorization (the IND number for that EUA is entered). For CBER biologics license applications, the supplement number is entered if known. See also the investigational new drug (IND) entry for the application type itself.
One application per form, and the multiple-product exception
Each form and submission pertains to a single application number. Where one piece promotes several products (price lists, formulary lists, multiple-product reminder advertisements, corporate communications), the form carries one application number and the other products are listed on an attached sheet giving application type and number, trade name and established name, with the labeling for each product included. For non-eCTD (paper) submissions of such materials, the instructions call for three specimens filed to a single application, with three forms, the labeling, and three copies of the attached sheet.
Listing the materials (item 7)
Each material is listed individually, one per line. Components of formulary kits and of professional or consumer kits are listed separately. Consumer and professional pieces are submitted separately, and item 7a asks for one designation (Professional or Consumer) based on the primary audience, with the other audience noted in the comments field (7f). Item 7b takes an FDA material-type code. The table below groups the examples named in the instructions.
| Group | FDA material-type codes named in the instructions |
|---|---|
| Print and mail | Print Ad, Direct Mail, Sales Aid, Reprint, Press Release, Promotional Labeling |
| Broadcast | TV, Radio |
| Internet and digital | www-website, www-soc-med, www-video, www-banner, www-mobile, www-ecomm, www-links, www-audio |
| Software and detailing aids | Electronic Detail Aid, PDURS (Prescription Drug Use Related Software) |
| Corrective communications | Corrective TV, Corrective Print Ad, Corrective Letter, Corrective Internet (correctives related to a Warning letter) |
| Kits and other | Formulary Kit, Training Materials, Drug Sample |
The instructions state that this is a list of examples (“etc.”), so the complete current code list is in the form instructions themselves.
Submission steps
- Confirm the piece is promotional labeling or advertising for a product under an NDA, ANDA, BLA or other listed application, and identify the single application number it belongs to.
- Complete items 1 to 7 for each piece: date submitted, application type and number, proprietary and established names, package insert date and ID of the current labeling, manufacturer, and the line-by-line material list.
- Complete the contact and signature items (8 to 12): return address including country, telephone, fax and email, the typed name and title of the responsible official or agent, signature and date of signature.
- For CBER products, complete item 13 to state whether the submission is draft or final (see below).
- Attach the materials and a copy of the current professional labeling and send them through the route that applies to the product. For human prescription drugs, the FDA CDER OPDP eCTD page (current as of 09/09/2025 when read) states that firms have been required to submit all promotional submissions electronically since 24 June 2021, under the guidance “Providing Regulatory Submissions in Electronic and Non-Electronic Format–Promotional Labeling and Advertising Materials for Human Prescription Drugs” (final, June 24, 2019).
The same FDA page directs technical, acknowledgment and rejection questions on electronic submissions to the CDER ESUB support team ([email protected]) and general OPDP questions to [email protected]. A response to an Untitled or Warning letter is sent as a cover letter only, with no Form 2253.
CDER and CBER: where the routes differ
| Point | CDER (drugs and therapeutic biologics) | CBER (biologics) |
|---|---|---|
| Receiving office in the 11/21 instructions | Office of Prescription Drug Promotion (OPDP) | CBER Document Control Center |
| Item 13 (draft or final) | Not described on the OPDP eCTD page read | Marked for CBER products only: Part I/Draft or Part II/Final |
| Electronic submission | Required for promotional submissions from 24 June 2021 per OPDP | CBER’s page (content current as of 03/16/2018) says final and draft may be submitted on paper or electronically |
The paper mailing addresses printed in the 11/21 supplement are dated and the electronic route now applies to human prescription drugs, so check the current FDA pages before sending anything on paper.
Timing phases
The rule is tied to dissemination, not to a calendar date. The phases below come from 21 CFR 314.81(b)(3)(i) and the CBER page.
- Before approval, optional draft review. CBER says draft materials not yet published or disseminated may be submitted for advisory comments, marked Part I/Draft in item 13. A draft direct-to-consumer television piece also needs two copies of an annotated storyboard with sequentially numbered frames, plus a video or animatic in a listed format.
- Accelerated approval. For materials intended for dissemination within 120 days after marketing approval, CBER says they go to the agency during pre-approval review with item 13 marked Part I/Draft. After that 120-day period, they are submitted at least 30 days before intended initial dissemination or publication. The CBER page cites 21 CFR 314.81(b)(3)(i), 314.550 and 601.45.
- At first use. For a prescription drug product, 21 CFR 314.81(b)(3)(i) puts the submission at the time of initial dissemination of the labeling and at the time of initial publication of the advertisement. Final CBER submissions are marked Part II/Final and include two copies of the final materials and two copies of current professional labeling.
Common mistakes the instructions guard against
- Putting more than one application number on a form without using the attached sheet for the other products.
- Combining consumer and professional pieces in one submission instead of submitting them separately.
- Listing a kit as a single line instead of listing each component.
- Grouping several pieces on one line rather than one material per line.
- Using an outdated edition of the form: the instructions mark previous editions as obsolete.
- Omitting the current professional labeling, which the regulation requires with each submission.
- Filing a form with a Warning-letter response, where FDA describes a cover letter only.
Related forms
Form 2253 is easily confused with other numbered FDA forms. It is separate from FDA Form 356h, the form used for the application itself, and from FDA Form 1572, the investigator statement used in clinical trials. The 2253 deals only with promotion after or ahead of marketing. Expedited-program designations such as fast track and priority review concern the review path, not promotional submissions.
FAQ
What is FDA Form 2253?
It is the transmittal form for advertisements and promotional labeling for human drugs and biologics, submitted with the materials and the current professional labeling.
Who must submit it?
For prescription drug products, the applicant, under 21 CFR 314.81(b)(3)(i), at initial dissemination of labeling or initial publication of an advertisement.
Can one form cover several products?
Only when the piece promotes several products: one application number goes on the form and the rest on an attached sheet, with labeling for each product.
Is electronic submission required?
For human prescription drug promotional submissions, FDA’s OPDP page states electronic submission has been required since 24 June 2021.
Is a draft submission allowed?
CBER describes draft submissions for advisory comment, marked Part I/Draft in item 13, for materials not yet published or disseminated.
Sources
- FDA, Form FDA 2253 Supplement (11/21) – Instructions, read 2026-11-12.
- FDA CBER, Submitting Biologics Advertising & Promotional Labeling (content current as of 03/16/2018), read 2026-11-12.
- 21 CFR 314.81, Cornell LII, read 2026-11-12.
- FDA CDER, OPDP eCTD (content current as of 09/09/2025), read 2026-11-12.
Data: FDA Form 2253 items 1-13: what each box asks for
Item-by-item summary of Form FDA 2253 compiled from the FDA instructions supplement (11/21) and the CBER advertising and promotional labeling page, read 2026-11-12.
Period covered: 2021/2026. Coverage: United States.
| Item | Field | What the FDA instructions describe |
|---|---|---|
| 1 | Date Submitted | Date the form and materials are sent to FDA |
| 2 | Application information | Application type (NDA, ANDA, BLA, PMA, or CDER IND for an authorized CDER EUA) and number; one application number per form; CBER BLAs: supplement number if known |
| 3 | Proprietary name | Proprietary name, with dosage form if part of the name |
| 4 | Established name | Established name; for biologics, the Product Code No. if known |
| 5 | Labeling date and ID | Package insert date and ID number of the most current labeling |
| 6 | Manufacturer | Manufacturer name; license number for biologics |
| 7 | Materials submitted | Each material listed individually; kit components listed separately; consumer and professional pieces submitted separately |
| 7a | Audience | Professional or Consumer, by primary audience; the other noted in comments |
| 7b | Material type | FDA material-type code (for example Print Ad, TV, www-website, Formulary Kit) |
| 7c-7f | Dissemination date, ID code, description, comments | Date of initial dissemination or publication; applicant's material ID code; description; comments on dissemination method and pieces meant to go together |
| 8-9 | Return address and contact | Return address including country; telephone, fax and email |
| 10-12 | Responsible official | Typed name and title of the responsible official or agent who answers inquiries; signature; date of signature |
| 13 | Biological products | For CBER products only: draft or final (Part I/Draft, Part II/Final) |
Sources
- Form FDA 2253 Supplement (11/21) - Instructions (accessed 2026-11-12)
- FDA CBER: Submitting Biologics Advertising & Promotional Labeling (accessed 2026-11-12)
Compiled by CASRAI from the sources above. Free to reuse under CC BY 4.0 with attribution.







